Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Abstract

Background Trials of statin therapy have had conflicting findings on the risk of development of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of published and unpublished data whether any relation exists between statin use and development of diabetes.Methods We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials from 1994 to 2009, for randomised controlled endpoint trials of statins. We included only trials with more than 1000 patients, with identical follow-up in both groups and duration of more than 1 year. We excluded trials of patients with organ transplants or who needed haemodialysis. We used the I(2) statistic to measure heterogeneity between trials and calculated risk estimates for incident diabetes with random-effect meta-analysis.Findings We identified 13 statin trials with 91 140 participants, of whom 4278 (2226 assigned statins and 2052 assigned control treatment) developed diabetes during a mean of 4 years. Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials. Meta-regression showed that risk of development of diabetes with statins was highest in trials with older participants, but neither baseline body-mass index nor change in LDL-cholesterol concentrations accounted for residual variation in risk. Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes.Interpretation Statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change.Funding None.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)61965-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

20 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 39 references

Research works printed but not linked: 2

  1. 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?, Ital Heart J, 1, 810
  2. Sabatine, 2004, High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy, Circulation, 110, 834

Cited by

See all 2,436

Metadata

Authors
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., Macfarlane, P. W., Packard, C. J., Stott, D. J., Westendorp, R. G., Shepherd, J., Davis, B. R., Pressel, S. L., Marchioli, R., Marfisi, R. M., Maggioni, A. P., Tavazzi, L., Tognoni, G., Kjekshus, J., Pedersen, T. R., Cook, T. J., Gotto, A. M., Clearfield, M. B., Downs, J. R., Nakamura, H., Ohashi, Y., Mizuno, K., Ray, K. K., & Ford, I.
Affiliations
  • British Heart Foundation (GB)
  • University of Glasgow (GB)
  • Cork University Hospital (IE)
  • University of Cambridge (GB)
  • Leiden University (NL)
  • Netherlands Consortium for Healthy Ageing (NL)
  • Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
  • Oslo University Hospital (NO)
  • Cornell University (US)
  • The University of Texas at San Antonio Health Science Center (US)
  • Mitsukoshi Health and Welfare Foundation (JP)
  • The University of Tokyo (JP)
  • Nippon Medical School (JP)
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-02
Volume
375
Issue
9716
Pages
735-742
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2115169717
Cited by
2,436
References
39
Citations by year
2026: 73 · 2025: 74 · 2024: 122 · 2023: 109 · 2022: 128 · 2021: 106 · 2020: 153 · 2019: 167 · 2018: 173 · 2017: 167 · 2016: 221 · 2015: 211 · 2014: 201 · 2013: 177 · 2012: 153
FWCI
29.98
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
statins, new-onset diabetes, diabetes risk, statin adverse effects, LDL cholesterol lowering, cardiovascular risk, statin trials, body mass index, age as risk factor
MeSH terms
Age Factors, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Risk Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Age Distribution, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. https://app.cochat.ai/papers/10.1016/s0140-6736(09)61965-6
The paper
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., Macfarlane, P. W., Packard, C. J., Stott, D. J., Westendorp, R. G., Shepherd, J., Davis, B. R., Pressel, S. L., Marchioli, R., Marfisi, R. M., . . . Ford, I. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. https://doi.org/10.1016/s0140-6736(09)61965-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.